The Influence of Early Measurements Onto the Estimated Kidney Dose in [177Lu][DOTA0,Tyr3]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors

Molecular Imaging and Biology

Volumn 17, Issue 5, 2015, Pages 726-734

  Delker, Andreas ^a   Ilhan, Harun ^a   Zach, Christian ^a   Brosch, Julia ^a   Gildehaus, Franz Josef ^a   Lehner, Sebastian ^a   Bartenstein, Peter ^a   Böning, Guido ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Dosimetry; Kidney dose; Lutetium 177; Neuroendocrine tumor; Peptide receptor radionuclide therapy

Indexed keywords

DOTATATE LU 177; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; ANTINEOPLASTIC AGENT; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE CALCULATION; DOSIMETRY; FEMALE; HALF LIFE TIME; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOCHEMISTRY; SCINTIGRAPHY; WHOLE BODY IMAGING; ANALOGS AND DERIVATIVES; KIDNEY; METABOLISM; NEUROENDOCRINE TUMORS; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; SCINTISCANNING;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RECEPTORS, PEPTIDE; WHOLE BODY IMAGING;

EID: 84941994460     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0839-3     Document Type: Article

References (34)

1. Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176
2. Bodei L, Mueller-Brand J, Baum RP et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816
3. van der Zwan WA, Bodei L, Mueller-Brand J, et al. (2014) GEP-NETS update: radionuclide therapy in neuroendocrine tumors. European journal of endocrinology / European Federation of Endocrine Societies
4. Koch W, Auernhammer CJ, Geisler J et al (2014) Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Mol Imaging 13:1–10
5. Bodei L, Cremonesi M, Grana CM et al (2012) Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging 39(Suppl 1):S93–S102
6. Kam BL, Teunissen JJ, Krenning EP et al (2012) Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39(Suppl 1):S103–S112
7. Konijnenberg M, Melis M, Valkema R et al (2007) Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nuclear Med: Off Public Soc Nuclear Med 48:134–142
8. Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122
9. 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res 2:49
10. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30:917–920
11. Ichihara T, Ogawa K, Motomura N et al (1993) Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nuclear Med: Off Public Soc Nuclear Med 34:2216–2221
12. Fleming JS (1979) A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol 24:176–180
13. Siegel JA, Thomas SR, Stubbs JB et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nuclear Med: Off Public Soc Nuclear Med 40:37S–61S
14. Berger MJ, Hubbell JH, Seltzer SM (2010) XCOM: photon cross section database (version 1.5). http://physics.nist.gov/xcom. National Institute of Standards and Technology, Gaithersburg
15. Kojima A, Takaki Y, Matsumoto M et al (1993) A preliminary phantom study on a proposed model for quantification of renal planar scintigraphy. Med Phys 20:33–37
16. Loevinger R, Berman M (1968) A formalism for calculation of absorbed dose from radionuclides. Phys Med Biol 13:205–217
17. Stabin M, Siegel J, Hunt J et al (2001) RADAR: the radiation dose assessment resource. J Nucl Med 42
18. Williams LE, Liu A, Yamauchi DM et al (2002) The two types of correction of absorbed dose estimates for internal emitters. Cancer 94:1231–1234
19. Stabin MG, Xu XG, Emmons MA et al (2012) RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J Nuclear Med: Off Public Soc Nuclear Med 53:1807–1813
20. Glatting G, Kletting P, Reske SN et al (2007) Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 34:4285–4292
21. Kletting P, Schimmel S, Kestler HA et al (2013) Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys 40:102504
22. Kletting P, Kull T, Reske SN, Glatting G (2009) Comparing time activity curves using the Akaike information criterion. Phys Med Biol 54:N501–N507
23. Guerriero F, Ferrari ME, Botta F et al (2013) Kidney dosimetry in (1)(7)(7)Lu and (9)(0)Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. BioMed Res Int 2013:935351
24. Baechler S, Hobbs RF, Prideaux AR et al (2008) Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys 35:1123–1134
25. Cremonesi M, Botta F, Di Dia A et al (2010) Dosimetry for treatment with radiolabelled somatostatin analogues. a review. Quart J Nuclear Med Molec Imag: Off Public Italian Assoc Nuclear Med 54:37–51
26. Garkavij M, Nickel M, Sjogreen-Gleisner K et al (2010) 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 116:1084–1092
27. Sandstrom M, Garske U, Granberg D et al (2010) Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 37:212–225
28. Beauregard JM, Hofman MS, Pereira JM et al (2011) Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imag: official Public Int Cancer Imag Soc 11:56–66
29. Sanders JC, Kuwert T, Hornegger J, Ritt P (2014) Quantitative SPECT/CT Imaging of Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Molec Imag Biol: MIB: Off Public Acad Molec Imag
30. 111In-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319–1325
31. 177Lu DOTA-NOC. Cancer Biother Radiopharm 22:406–416
32. Helisch A, Forster GJ, Reber H et al (2004) Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1386–1392
33. Spiess AN, Neumeyer N (2010) An evaluation of R2 as an inadequate measure for nonlinear models in pharmacological and biochemical research: a Monte Carlo approach. BMC Pharmacol 10:6
34. Lassmann M, Chiesa C, Flux G et al (2011) EANM dosimetry committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 38:192–200